Praxis Precision Medicines Management
Management criteria checks 4/4
Praxis Precision Medicines' CEO is Marcio De'Souza, appointed in Apr 2020, has a tenure of 4.58 years. total yearly compensation is $2.12M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth $1.27M. The average tenure of the management team and the board of directors is 3.9 years and 3 years respectively.
Key information
Marcio De'Souza
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 29.5% |
| CEO tenure | 4.6yrs |
| CEO ownership | 0.09% |
| Management average tenure | 3.9yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$151m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$625k | -US$123m |
| Sep 30 2023 | n/a | n/a | -US$138m |
| Jun 30 2023 | n/a | n/a | -US$157m |
| Mar 31 2023 | n/a | n/a | -US$183m |
| Dec 31 2022 | US$6m | US$625k | -US$214m |
| Sep 30 2022 | n/a | n/a | -US$231m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$11m | US$571k | -US$167m |
| Sep 30 2021 | n/a | n/a | -US$135m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$88m |
| Dec 31 2020 | US$12m | US$385k | -US$70m |
Compensation vs Market: Marcio's total compensation ($USD2.12M) is below average for companies of similar size in the US market ($USD5.36M).
Compensation vs Earnings: Marcio's compensation has been consistent with company performance over the past year.
CEO
Marcio De'Souza (45 yo)
4.6yrs
Tenure
US$2,120,512
Compensation
Mr. Marcio Silva De'Souza has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in April 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.6yrs | US$2.12m | 0.089% $ 1.3m | |
| CFO & Treasurer | 3.5yrs | US$1.02m | 0.019% $ 272.1k | |
| General Counsel & Secretary | 4.4yrs | US$843.11k | 0.013% $ 180.7k | |
| Co-Founder & Chief Scientific Officer | 6.8yrs | no data | no data | |
| VP of Finance & Principal Accounting Officer | no data | no data | 0.0085% $ 122.2k | |
| Chief Technical Operations Officer | 2.9yrs | no data | no data | |
| VP of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief People Officer | 3.9yrs | no data | 0.016% $ 225.5k | |
| Chief Regulatory & Quality Officer | 4.2yrs | no data | no data | |
| Chief Business Officer | 2.9yrs | no data | no data | |
| Chief of Staff | 2.7yrs | no data | no data |
3.9yrs
Average Tenure
45yo
Average Age
Experienced Management: PRAX's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.6yrs | US$2.12m | 0.089% $ 1.3m | |
| Independent Director | 7.9yrs | US$79.28k | 0.010% $ 145.9k | |
| Independent Chairman of the Board | 4.2yrs | US$104.37k | 0.027% $ 384.4k | |
| Independent Director | 5.7yrs | US$82.87k | 0.0010% $ 14.5k | |
| Independent Director | 3.6yrs | US$76.28k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$78.87k | 0.0052% $ 74.2k | |
| Independent Director | 3.6yrs | US$72.87k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Chairman of the Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data |
3.0yrs
Average Tenure
68yo
Average Age
Experienced Board: PRAX's board of directors are considered experienced (3 years average tenure).